Celltrion USA Enters Into Agreement with Express Scripts and Cigna Healthcare to Expand Access to ZYMFENTRA

COOL VALLEY (dpa-AFX) – Celltrion USA announced that it has entered into an agreement with Cigna Healthcare, the health insurer of Cigna Group, and Express Scripts, the pharmaceutical insurer of Cigna Group’s Evernorth and one of the nation’s largest health insurers, to expand patient access to ZYMFENTRA (infliximab-dyyb), the first and only U.S. Food and Drug Administration (FDA)-approved subcutaneous infliximab.

The agreement, which begins August 1, 2024, lists ZYMFENTRA as a preferred drug on Cigna’s medical prescription form, which serves 16.1 million plan members.

ZYMFENTRA was approved by the FDA in October 2023 for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD) following treatment with an intravenously administered infliximab product.

Copyright(c) 2024 RTTNews.com. All rights reserved.

Copyright RTT News/dpa-AFX